Rosemont Pharmaceuticals appoints new CFO

Rosemont would like to announce that Tim Busby, CFO and Interim CEO, has made the decision to retire from his role as CFO at Rosemont and focus on his external Board roles and charitable foundation.

Tim’s impact on Rosemont for over 5 years is unquestionable and is the main reason he was asked to support Rosemont as interim CEO from July 2025. We’re so very thankful for this support, not least over the past 6 months, where his guidance to the board and the business has been unwavering.

We’re delighted to announce we have recruited his replacement and welcome Gavin Wood as our new CFO, as of the 1st of December 2025.

Gavin is a seasoned, global CFO who most recently was CFO for Adaptimune Therapeutics, a pioneer in the development of cell therapies. With over 30 years of experience managing global teams covering Finance, Legal and IT, the Board is extremely pleased that he will bring this wealth of knowledge to Rosemont as we continue to grow.

The team is very grateful that Tim will remain with Rosemont over the next couple of months to support a full onboarding program with Gavin.

Please join us in welcoming Gavin and thanking Tim for his contributions to Rosemont.

 

 

ROS000238-004 DOP Dec 2025